2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …
Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
Does the long-term administration of proton pump inhibitors increase the risk of adverse cardiovascular outcomes? A ChatGPT powered umbrella review
E Teperikidis, A Boulmpou, V Potoupni, S Kundu… - Acta …, 2023 - Taylor & Francis
Abstract Background Proton pump inhibitors (PPIs) are commonly prescribed for the
treatment of acid-related disorders. In the context of coronary artery disease (CAD), PPIs are …
treatment of acid-related disorders. In the context of coronary artery disease (CAD), PPIs are …
Current management of gastro-oesophageal reflux disease—treatment costs, safety profile, and effectiveness: a narrative review
T Lata, J Trautman, P Townend… - Gastroenterology …, 2023 - academic.oup.com
Background The purpose of this study was to review the current management of gastro-
oesophageal reflux disease (GORD), including treatment costs, safety profile and …
oesophageal reflux disease (GORD), including treatment costs, safety profile and …
Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship
Proton pump inhibitors (PPIs) have been available for over three decades and are among
the most commonly prescribed medications. They are effective in treating a variety of gastric …
the most commonly prescribed medications. They are effective in treating a variety of gastric …
[HTML][HTML] The Efficacy and Safety of Proton Pump Inhibitors Combining Dual Antiplatelet Therapy in Patients with Coronary Intervention: A Systematic Review, Meta …
S Liang, M Ma, Y Chen, J Zhang, J Li… - Reviews in …, 2023 - imrpress.com
Background: Proton pump inhibitors (PPIs) are used to prevent gastrointestinal hemorrhage
in patients with coronary treatment undergoing dual antiplatelet therapy (DAPT). Methods: A …
in patients with coronary treatment undergoing dual antiplatelet therapy (DAPT). Methods: A …
Cardiovascular Compatibility of Proton Pump Inhibitors: Practice Recommendations
J Dalal, AL Dutta, J Hiremath, SS Iyengar… - Cardiology and …, 2023 - Springer
This manuscript aims to critically evaluate the current evidence regarding adverse
cardiovascular effects associated with proton pump inhibitors (PPIs) in patients with …
cardiovascular effects associated with proton pump inhibitors (PPIs) in patients with …
Pre-existing proton pump inhibitor treatment and short-term prognosis of acute myocardial infarction patients
J Xie, Q Chen, D He - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Introduction: Evidence suspects proton pump inhibitor (PPI) use is risk factor of poor
prognosis of acute myocardial infarction (AMI). We aimed to investigate the association …
prognosis of acute myocardial infarction (AMI). We aimed to investigate the association …
[HTML][HTML] β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous …
S Zhang, Y Wu, C Lv, H Liu, Y Wang, L Dong… - Hellenic Journal of …, 2023 - Elsevier
Background β1-blockers could improve clinical outcomes in patients with coronary artery
disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover …
disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover …
Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and …
X Luo, M Hou, S He, X Yang, P Zhang… - Frontiers in …, 2023 - frontiersin.org
Background: Proton pump inhibitors (PPIs) are usually prescribed to prevent gastrointestinal
(GI) complications in patients receiving dual antiplatelet therapy (DAPT). This systematic …
(GI) complications in patients receiving dual antiplatelet therapy (DAPT). This systematic …
Optimal antiplatelet therapy for patients after antiplatelet therapy induced gastrointestinal bleeding: timing
B Xiao, Z Ye, R Cheng, Z Han, S Wu, G Wang… - Internal and Emergency …, 2023 - Springer
Adjusting antiplatelet strategies after antiplatelet-associated gastrointestinal bleeding (GIB)
is a complex clinical challenge. To assess the risk of outcomes at different times of …
is a complex clinical challenge. To assess the risk of outcomes at different times of …